fluconazole has been researched along with Acute Myelogenous Leukemia in 72 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients undergoing chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome, posaconazole prevented invasive fungal infections more effectively than did either fluconazole or itraconazole and improved overall survival." | 9.12 | Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. ( Angulo-Gonzalez, D; Cornely, OA; Goh, YT; Hardalo, C; Helfgott, D; Holowiecki, J; Maertens, J; Perfect, J; Petrini, M; Stockelberg, D; Suresh, R; Ullmann, AJ; Walsh, TJ; Winston, DJ, 2007) |
| "We performed a randomized, controlled study comparing the prophylactic effects of capsule forms of fluconazole (n = 110) and itraconazole (n = 108) in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) during and after chemotherapy." | 9.12 | The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study. ( Aoyama, Y; Ito, Y; Kanamaru, A; Kiguchi, T; Masaoka, T; Matsuda, M; Matsuura, Y; Mugitani, A; Ohyashiki, K; Sakamoto, E; Takeuchi, M; Tamura, K; Urabe, A; Wakita, H; Yoshida, I, 2007) |
| "Fluconazole is a safe and effective agent with significant activity against chronic disseminated candidiasis." | 9.07 | Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. ( Anaissie, E; Barnett, K; Bodey, GP; Bow, E; David, C; Defelice, R; Downs, N; File, T; Kantarjian, H; Karam, G, 1991) |
| "Posaconazole is superior to fluconazole (FLU) and itraconazole (ITRA) in the prevention of invasive fungal diseases (IFDs) in neutropenic patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)." | 7.85 | Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain. ( Aragón, B; Cámara, R; Gozalbo, I; Grau, S; Jurado, M; Sanz, J, 2017) |
| "Posaconazole is superior to fluconazole/itraconazole in preventing invasive fungal diseases (IFDs) in neutropenic patients." | 7.83 | Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital. ( Chan, TS; Gill, H; Hwang, YY; Kwong, YL; Marcella, SW, 2016) |
| "Posaconazole prophylaxis during induction chemotherapy for acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) has been shown to significantly decrease the incidence of invasive fungal disease (IFD) and increase overall survival in a trial setting, but only small real-life studies have been published." | 7.83 | Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes. ( Björkholm, M; Blennow, O; Cederlund, K; Dahlén, T; Kalin, M; Ljungman, P; Nordlander, A, 2016) |
| "These findings suggest that oral itraconazole could be effective for preventing invasive gingival aspergillosis in neutropenic patients with acute leukemia and warrants further randomized investigation." | 7.71 | Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia. ( Fujihara, M; Kyo, T; Mikami, Y; Myoken, Y; Sugata, T, 2002) |
| "Multiple necrotizing skin lesions due to Fusarium solani in an elderly man with acute myelogenous leukemia is described." | 7.69 | Fusarium solani infection in a patient with acute myelogenous leukemia--a case report. ( Kumar, BR; Kumar, RR; Lakshmaiah, KC; Shafiulla, M; Sridhar, H, 1997) |
| " We report a case of hepatosplenic candidiasis in a patient with acute myelogenous leukemia who had clinical and radiographic improvement during fluconazole therapy." | 7.68 | Fluconazole in the treatment of hepatosplenic candidiasis. ( Adelman, HM; Altus, P; Flannery, MT; Saba, H; Simmons, DB; Wallach, PM, 1992) |
| "Fungal infections are a major cause of morbidity and mortality in patients undergoing induction chemotherapy for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)." | 6.71 | Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. ( Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Koller, C; Kontoyiannis, D; Mattiuzzi, GN; Munsell, M; Raad, I; Shen, Y, 2003) |
| "Fluconazole prophylaxis was administered following 44 cycles (fluconazole group) and not given in 32 cycles (control group)." | 5.36 | Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis. ( Deremer, D; Dobbins, R; Eisa, N; El-Geneidy, M; Hall, P; Jillella, A; Lewis, G; Ustun, C, 2010) |
| "To compare the efficacy of caspofungin vs fluconazole prophylaxis against proven or probable invasive fungal disease and invasive aspergillosis during neutropenia following acute myeloid leukemia chemotherapy." | 5.30 | Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial. ( Alexander, S; Callahan, C; Chen, L; Dang, H; Dvorak, CC; Esbenshade, AJ; Fisher, BT; Nieder, M; Sung, L; Villaluna, D; Wiley, JM; Wingard, JR; Zaoutis, T; Zerr, D, 2019) |
| "The objective of this study was to assess the costs and effectiveness (avoided invasive fungal infections - IFIs; overall mortality) of prophylaxis with posaconazole 200 mg per os TID and standard azoles (fluconazole 400 mg per os OD, itraconazole 200 mg per os BID) in neutropenic patients with acute myelogenous leukaemia or myelodysplastic syndromes." | 5.14 | [Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome]. ( Lazzaro, C, 2010) |
| "We performed a randomized, controlled study comparing the prophylactic effects of capsule forms of fluconazole (n = 110) and itraconazole (n = 108) in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) during and after chemotherapy." | 5.12 | The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study. ( Aoyama, Y; Ito, Y; Kanamaru, A; Kiguchi, T; Masaoka, T; Matsuda, M; Matsuura, Y; Mugitani, A; Ohyashiki, K; Sakamoto, E; Takeuchi, M; Tamura, K; Urabe, A; Wakita, H; Yoshida, I, 2007) |
| "In patients undergoing chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome, posaconazole prevented invasive fungal infections more effectively than did either fluconazole or itraconazole and improved overall survival." | 5.12 | Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. ( Angulo-Gonzalez, D; Cornely, OA; Goh, YT; Hardalo, C; Helfgott, D; Holowiecki, J; Maertens, J; Perfect, J; Petrini, M; Stockelberg, D; Suresh, R; Ullmann, AJ; Walsh, TJ; Winston, DJ, 2007) |
| "Fluconazole is a safe and effective agent with significant activity against chronic disseminated candidiasis." | 5.07 | Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. ( Anaissie, E; Barnett, K; Bodey, GP; Bow, E; David, C; Defelice, R; Downs, N; File, T; Kantarjian, H; Karam, G, 1991) |
| "Posaconazole is superior to fluconazole (FLU) and itraconazole (ITRA) in the prevention of invasive fungal diseases (IFDs) in neutropenic patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)." | 3.85 | Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain. ( Aragón, B; Cámara, R; Gozalbo, I; Grau, S; Jurado, M; Sanz, J, 2017) |
| "Posaconazole prophylaxis during induction chemotherapy for acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) has been shown to significantly decrease the incidence of invasive fungal disease (IFD) and increase overall survival in a trial setting, but only small real-life studies have been published." | 3.83 | Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes. ( Björkholm, M; Blennow, O; Cederlund, K; Dahlén, T; Kalin, M; Ljungman, P; Nordlander, A, 2016) |
| "Posaconazole is superior to fluconazole/itraconazole in preventing invasive fungal diseases (IFDs) in neutropenic patients." | 3.83 | Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital. ( Chan, TS; Gill, H; Hwang, YY; Kwong, YL; Marcella, SW, 2016) |
| "In patients undergoing induction chemotherapy for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), posaconazole has been proven more effective in the prevention of invasive fungal infection (IFI) than fluconazole or itraconazole (standard azoles) The current analysis seeks to estimate the cost effectiveness of prophylactic posaconazole compared with standard azoles in AML or MDS patients with severe chemotherapy-induced neutropenia in Sweden." | 3.80 | Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden. ( Åkerborg, Ö; Björkholm, M; Höglund, M; Lundberg, J, 2014) |
| "These findings suggest that oral itraconazole could be effective for preventing invasive gingival aspergillosis in neutropenic patients with acute leukemia and warrants further randomized investigation." | 3.71 | Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia. ( Fujihara, M; Kyo, T; Mikami, Y; Myoken, Y; Sugata, T, 2002) |
| "Multiple necrotizing skin lesions due to Fusarium solani in an elderly man with acute myelogenous leukemia is described." | 3.69 | Fusarium solani infection in a patient with acute myelogenous leukemia--a case report. ( Kumar, BR; Kumar, RR; Lakshmaiah, KC; Shafiulla, M; Sridhar, H, 1997) |
| "Infections with fluconazole-resistant Candida albicans isolate have rarely been described in clinical settings other than oropharyngeal candidiasis in patients with late-stage AIDS." | 3.69 | Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. ( Dix, S; Falconer, DJ; Geller, R; Gilmore, C; Nolte, FS; Parkinson, T; Williams, J; Wingard, JR, 1997) |
| "Two pediatric leukemic patients with hepatosplenic candidiasis during multidrug antileukemic chemotherapy successfully underwent bone marrow transplantation (BMT) after aggressive antifungal chemotherapy employing fluconazole and amphotericin B with or without splenectomy." | 3.69 | Successful peritransplant therapy in children with active hepatosplenic candidiasis. ( Ichihara, T; Katayama, K; Koizumi, S; Konishi, M; Maekawa, S; Seki, H; Tamaru, Y; Taniguchi, N; Yamagami, M, 1994) |
| " One patient had developed a chronic systemic candidiasis during consolidation chemotherapy and received prophylactic oral or iv fluconazole (200 mg daily) throughout BMT." | 3.69 | Successful bone marrow transplantation in patients with previous invasive fungal infections: report of four cases. ( Altés, A; Brunet, S; Domingo-Albós, A; Martínez, C; Martino, R; Nomdedéu, J; Sureda, A, 1994) |
| " We report a case of hepatosplenic candidiasis in a patient with acute myelogenous leukemia who had clinical and radiographic improvement during fluconazole therapy." | 3.68 | Fluconazole in the treatment of hepatosplenic candidiasis. ( Adelman, HM; Altus, P; Flannery, MT; Saba, H; Simmons, DB; Wallach, PM, 1992) |
| "Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and allogeneic hematopoietic cell transplant recipients were randomly assigned to receive caspofungin empirically (arm A) or preemptively (arm B), while receiving fluconazole 400 mg daily prophylactically." | 3.30 | Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer. ( Ameye, L; Aoun, M; Barnes, R; Baron, F; Bertz, H; Blijlevens, N; Bochud, PY; Chantepie, S; Cheung, KJ; Coiteux, V; Cordonnier, C; Donnelly, JP; Drgona, L; Heinz, WJ; Hepler, DA; Lamoth, F; Llorente, CC; Lodewyck, T; Loeffler, J; Maertens, J; Marchetti, O; Meert, L; Paesmans, M; Ráčil, Z; Robin, C; Schaefer-Prokop, C; Schwarzinger, M; Selleslag, D; Turlure, P; Vandercam, B; Verweij, P, 2023) |
| "Quizartinib is an oral, highly potent and selective next-generation FMS-like tyrosine kinase 3 (FLT3) inhibitor under investigation in patients with FLT3-internal tandem duplication-mutated acute myeloid leukaemia." | 2.90 | Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite. ( Gammon, G; Kankam, M; Li, J; Trone, D, 2019) |
| "Fungal infections are a major cause of morbidity and mortality in patients undergoing induction chemotherapy for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)." | 2.71 | Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. ( Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Koller, C; Kontoyiannis, D; Mattiuzzi, GN; Munsell, M; Raad, I; Shen, Y, 2003) |
| "Voriconazole was dominated by posaconazole." | 2.53 | Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis. ( Chai, LY; Khoo, AL; Lim, BP; Ong, B; Tan, BH; Tan, G; Tee, C; Teng, M; Zhao, YJ, 2016) |
| "We report a patient with acute myeloid leukemia who developed HSC during post-remission consolidation chemotherapy and was treated with a prolonged course of caspofungin followed by fluconazole." | 2.45 | Successful intensive chemotherapy followed by autologous hematopoietic cell transplantation in a patient with acute myeloid leukemia and hepatosplenic candidiasis: case report and review of literature. ( Chia, HY; Koh, LP; Liu, TC; Poon, LM; Tan, LK, 2009) |
| "A 3-year-old boy with a history of acute myeloid leukemia was hospitalized in Omid Hospital, Isfahan, Iran." | 1.91 | Catheter-associated blood stream infections due to Candida pararugosa in a patient with acute myeloid leukemia: A case report. ( Abbasi, K; Badali, H; Fakhim, H; Ghafel, S; Nasri, E; Rizi, MH; Shelerangkon, M; Vaezi, A, 2023) |
| "Pediatric acute myeloid leukemia (AML) is a challenging disease to treat in low- and middle-income countries (LMICs)." | 1.72 | Outcomes of pediatric acute myeloid leukemia treatment in Western Kenya. ( Kaspers, GJL; Kipng'etich, M; Klein, K; Langat, S; Mostert, S; Njuguna, F; Olbara, G; van Weelderen, RE; Vik, TA, 2022) |
| "Develop a physiologically based pharmacokinetic (PBPK) model of ivosidenib using in vitro and clinical PK data from healthy participants (HPs), refine it with clinical data on ivosidenib co-administered with itraconazole, and develop a model for patients with acute myeloid leukemia (AML) and apply it to predict ivosidenib drug-drug interactions (DDI)." | 1.56 | Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ( Fan, B; Ke, A; Le, K; Prakash, C; Yang, H, 2020) |
| "Patients with acute myeloid leukemia (AML) during induction chemotherapy and those who receive allogeneic hematopoietic stem cell transplantation (HSCT) are at higher risk of invasive fungal infections (IFI)." | 1.43 | Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation. ( Audisio, E; Aversa, F; Bruno, B; Busca, A; Candoni, A; Delia, M; Monaco, F; Mordini, N; Pagano, L; Passera, R; Vacca, A, 2016) |
| "Treatment with voriconazole was promptly started with success." | 1.43 | Acute isolated appendicitis due to Aspergillus carneus in a neutropenic child with acute myeloid leukemia. ( Bergami, E; Cavanna, C; Decembrino, N; Introzzi, F; Lallitto, F; Mangione, F; Marone, P; Tamarozzi, F; Tortorano, AM; Zecca, M, 2016) |
| "Posaconazole was introduced as the primary antifungal prophylaxis (PAP) in acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) patients during remission induction chemotherapy." | 1.42 | Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations. ( Cho, SY; Choi, JH; Choi, JK; Choi, SM; Kim, HJ; Kim, SH; Kim, YJ; Lee, DG; Lee, HJ; Min, WS; Park, SH; Yoo, JH, 2015) |
| "There were 91 patients with acute myeloid leukemia (AML), 51 with acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL), and 68 with ATL." | 1.39 | Distinct clinical features of infectious complications in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis in the Nagasaki transplant group. ( Ando, K; Fukushima, T; Hata, T; Honda, S; Imaizumi, Y; Imanishi, D; Itonaga, H; Matsuo, E; Miyazaki, Y; Moriuchi, Y; Onimaru, Y; Sato, S; Sawayama, Y; Taguchi, J; Tsushima, H; Yamasaki, R; Yoshida, S, 2013) |
| "Post-induction aplasia for acute myeloid leukemia/myelodysplastic syndrome is a high-risk period for invasive fungal diseases." | 1.38 | Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. ( Ananda-Rajah, MR; Bajel, A; Cheng, A; Downey, MT; Grigg, A; Slavin, MA; Spelman, T; Thursky, KT; Vincent, J, 2012) |
| "We describe two patients with acute myelogenous leukemia who developed cervical lymphadenitis and chronic disseminated infection due to Candida albicans." | 1.37 | Candida albicans cervical lymphadenitis in patients who have acute myeloid leukemia. ( Alsan, MM; Baden, LR; DeAngelo, DJ; Hammond, SP; Issa, NC; Milner, DA, 2011) |
| "Pulmonary aspergillosis was the most common causative agent, and no patients showed candidemia, or hepatosplenic candidiasis." | 1.37 | Invasive fungal infections in pediatric patients with hematologic malignancies receiving oral amphotericin B solution and early intravenous administration of fluconazole. ( Kato, K; Kojima, S; Matsumoto, K; Watanabe, N, 2011) |
| "Posaconazole was associated with an overall cost savings (range = $Can1,765 to $Can4,505) in all of the scenarios evaluated." | 1.37 | Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis. ( Dranitsaris, G; Khoury, H, 2011) |
| "Fluconazole prophylaxis was administered following 44 cycles (fluconazole group) and not given in 32 cycles (control group)." | 1.36 | Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis. ( Deremer, D; Dobbins, R; Eisa, N; El-Geneidy, M; Hall, P; Jillella, A; Lewis, G; Ustun, C, 2010) |
| "A 79-year-old male with acute myelogenous leukemia developed acute right knee arthritis during admission, after the use of broad-spectrum antibiotics before chemotherapy." | 1.34 | An unusual case of Candida tropicalis and Candida krusei arthritis in a patient with acute myelogenous leukemia before chemotherapy. ( Chang, HN; Chen, WS; Chou, CT; Chou, YL; Tsai, CY; Wang, HP; Yen, YF, 2007) |
| "She had complications of brain abscess at the WBC nadir after the second course of induction therapy." | 1.34 | [Improved outcome in brain abscess during induction in acute myelocytic leukemia]. ( Hino, M; Ichihara, H; Kanashima, H; Koh, H; Koh, KR; Nakamae, H; Nakane, T; Sakamoto, E; Takeoka, Y; Yamane, T, 2007) |
| "Invasive fungal infections are fatal complications for patients on chemotherapy, and antifungal prophylactic treatment has been commonly recommended." | 1.33 | Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy. ( Kawasugi, K; Morimoto, T; Nomura, K, 2006) |
| "Hepatosplenic candidiasis is increasingly observed in patients with a haematological malignancy who have received chemotherapy." | 1.29 | [Hepatosplenic candidiasis in patients treated for hemato-oncological disorders]. ( Huijgens, PC; Sibinga, L; Zweegman, S, 1994) |
| "06 L/kg, and terminal elimination half-life 16." | 1.28 | Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. ( Amantea, M; Lee, JW; Pizzo, PA; Seibel, NL; Walsh, TJ; Whitcomb, P, 1992) |
| " capitatum are usually sensitive to the azole compounds the explanation may be a too low daily dosage for the treatment of severely immunocompromised hosts." | 1.28 | [Trichosporon capitatum septicemia in immunosuppressed patients]. ( Bergerat, JP; Dufour, P; Herbrecht, R; Koenig, H; Liu, KL; Maloisel, F; Oberling, F; Waller, J, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.39) | 18.7374 |
| 1990's | 17 (23.61) | 18.2507 |
| 2000's | 24 (33.33) | 29.6817 |
| 2010's | 24 (33.33) | 24.3611 |
| 2020's | 6 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, Y | 1 |
| Dong, G | 1 |
| Li, H | 1 |
| Liu, N | 1 |
| Zhang, W | 1 |
| Sheng, C | 1 |
| van Weelderen, RE | 1 |
| Njuguna, F | 1 |
| Klein, K | 1 |
| Mostert, S | 1 |
| Langat, S | 1 |
| Vik, TA | 1 |
| Olbara, G | 1 |
| Kipng'etich, M | 1 |
| Kaspers, GJL | 1 |
| Maertens, J | 2 |
| Lodewyck, T | 1 |
| Donnelly, JP | 1 |
| Chantepie, S | 1 |
| Robin, C | 1 |
| Blijlevens, N | 1 |
| Turlure, P | 1 |
| Selleslag, D | 1 |
| Baron, F | 1 |
| Aoun, M | 1 |
| Heinz, WJ | 1 |
| Bertz, H | 2 |
| Ráčil, Z | 1 |
| Vandercam, B | 1 |
| Drgona, L | 1 |
| Coiteux, V | 1 |
| Llorente, CC | 1 |
| Schaefer-Prokop, C | 1 |
| Paesmans, M | 1 |
| Ameye, L | 1 |
| Meert, L | 1 |
| Cheung, KJ | 1 |
| Hepler, DA | 1 |
| Loeffler, J | 1 |
| Barnes, R | 1 |
| Marchetti, O | 1 |
| Verweij, P | 1 |
| Lamoth, F | 1 |
| Bochud, PY | 1 |
| Schwarzinger, M | 1 |
| Cordonnier, C | 1 |
| Nasri, E | 1 |
| Vaezi, A | 1 |
| Shelerangkon, M | 1 |
| Rizi, MH | 1 |
| Ghafel, S | 1 |
| Abbasi, K | 1 |
| Badali, H | 1 |
| Fakhim, H | 1 |
| Silva, WFD | 1 |
| Mendes, FR | 1 |
| Melo, RDCB | 1 |
| Velloso, EDRP | 1 |
| Rocha, V | 1 |
| Rego, EM | 1 |
| Fisher, BT | 1 |
| Zaoutis, T | 1 |
| Dvorak, CC | 1 |
| Nieder, M | 1 |
| Zerr, D | 1 |
| Wingard, JR | 2 |
| Callahan, C | 1 |
| Villaluna, D | 1 |
| Chen, L | 1 |
| Dang, H | 1 |
| Esbenshade, AJ | 1 |
| Alexander, S | 1 |
| Wiley, JM | 1 |
| Sung, L | 1 |
| de Lange, DW | 1 |
| Brüggemann, RJM | 1 |
| Prakash, C | 1 |
| Fan, B | 1 |
| Ke, A | 1 |
| Le, K | 1 |
| Yang, H | 1 |
| Berking, S | 1 |
| Doedens, D | 1 |
| Horns, H | 1 |
| Fiegl, M | 1 |
| Ostermann, H | 1 |
| Rieger, CT | 1 |
| Cámara, R | 1 |
| Gozalbo, I | 1 |
| Jurado, M | 1 |
| Sanz, J | 1 |
| Aragón, B | 1 |
| Grau, S | 1 |
| Manning, MA | 1 |
| Kuo, PH | 1 |
| Yeager, AM | 1 |
| Li, J | 1 |
| Kankam, M | 1 |
| Trone, D | 1 |
| Gammon, G | 1 |
| Heng, SC | 1 |
| Slavin, MA | 2 |
| Al-Badriyeh, D | 1 |
| Kirsa, S | 1 |
| Seymour, JF | 1 |
| Grigg, A | 2 |
| Thursky, K | 1 |
| Bajel, A | 2 |
| Nation, RL | 1 |
| Kong, DC | 1 |
| Drognitz, K | 1 |
| Lübbert, M | 1 |
| Lundberg, J | 1 |
| Höglund, M | 1 |
| Björkholm, M | 2 |
| Åkerborg, Ö | 1 |
| Dahlén, T | 1 |
| Kalin, M | 1 |
| Cederlund, K | 1 |
| Nordlander, A | 1 |
| Ljungman, P | 1 |
| Blennow, O | 1 |
| Tüfekçi, Ö | 1 |
| Yılmaz Bengoa, Ş | 1 |
| Demir Yenigürbüz, F | 1 |
| Şimşek, E | 1 |
| Karapınar, TH | 1 |
| İrken, G | 1 |
| Ören, H | 1 |
| Cho, SY | 2 |
| Lee, DG | 3 |
| Choi, JK | 2 |
| Lee, HJ | 2 |
| Kim, SH | 2 |
| Park, SH | 2 |
| Choi, SM | 3 |
| Choi, JH | 3 |
| Yoo, JH | 3 |
| Kim, YJ | 3 |
| Kim, HJ | 3 |
| Min, WS | 3 |
| Back, H | 1 |
| Kang, S | 1 |
| Lee, EK | 1 |
| Chan, TS | 1 |
| Marcella, SW | 1 |
| Gill, H | 1 |
| Hwang, YY | 1 |
| Kwong, YL | 1 |
| Zhao, YJ | 1 |
| Khoo, AL | 1 |
| Tan, G | 1 |
| Teng, M | 1 |
| Tee, C | 1 |
| Tan, BH | 1 |
| Ong, B | 1 |
| Lim, BP | 1 |
| Chai, LY | 1 |
| Decembrino, N | 1 |
| Zecca, M | 1 |
| Tortorano, AM | 1 |
| Mangione, F | 1 |
| Lallitto, F | 1 |
| Introzzi, F | 1 |
| Bergami, E | 1 |
| Marone, P | 1 |
| Tamarozzi, F | 1 |
| Cavanna, C | 1 |
| Busca, A | 1 |
| Candoni, A | 1 |
| Audisio, E | 1 |
| Passera, R | 1 |
| Bruno, B | 1 |
| Monaco, F | 1 |
| Mordini, N | 1 |
| Vacca, A | 1 |
| Delia, M | 1 |
| Aversa, F | 1 |
| Pagano, L | 1 |
| Karthaus, M | 1 |
| Stam, WB | 1 |
| O'Sullivan, AK | 1 |
| Rijnders, B | 1 |
| Lugtenburg, E | 1 |
| Span, LF | 1 |
| Janssen, JJ | 1 |
| Jansen, JP | 1 |
| Poon, LM | 1 |
| Chia, HY | 1 |
| Tan, LK | 1 |
| Liu, TC | 1 |
| Koh, LP | 1 |
| Teyton, P | 1 |
| Baillet, G | 1 |
| Hindié, E | 1 |
| Filmont, JE | 1 |
| Sarandi, F | 1 |
| Toubert, ME | 1 |
| Moretti, JL | 1 |
| Lazzaro, C | 1 |
| Dranitsaris, G | 1 |
| Khoury, H | 1 |
| Lewis, G | 1 |
| Hall, P | 1 |
| Eisa, N | 1 |
| Deremer, D | 1 |
| Dobbins, R | 1 |
| El-Geneidy, M | 1 |
| Jillella, A | 1 |
| Ustun, C | 1 |
| Watanabe, N | 1 |
| Matsumoto, K | 1 |
| Kojima, S | 1 |
| Kato, K | 1 |
| Alsan, MM | 1 |
| Issa, NC | 1 |
| Hammond, SP | 1 |
| Milner, DA | 1 |
| DeAngelo, DJ | 1 |
| Baden, LR | 1 |
| Ananda-Rajah, MR | 1 |
| Downey, MT | 1 |
| Spelman, T | 1 |
| Cheng, A | 1 |
| Thursky, KT | 1 |
| Vincent, J | 1 |
| Itonaga, H | 1 |
| Taguchi, J | 1 |
| Fukushima, T | 1 |
| Tsushima, H | 1 |
| Sato, S | 1 |
| Ando, K | 1 |
| Sawayama, Y | 1 |
| Matsuo, E | 1 |
| Yamasaki, R | 1 |
| Onimaru, Y | 1 |
| Imanishi, D | 1 |
| Imaizumi, Y | 1 |
| Yoshida, S | 1 |
| Hata, T | 1 |
| Moriuchi, Y | 1 |
| Honda, S | 1 |
| Miyazaki, Y | 1 |
| Ratip, S | 1 |
| Odabaşi, Z | 1 |
| Karti, S | 1 |
| Cetiner, M | 1 |
| Yeğen, C | 1 |
| Cerikcioğlu, N | 1 |
| Bayik, M | 1 |
| Korten, V | 1 |
| Fishman, JA | 1 |
| Kubak, BM | 1 |
| Mattiuzzi, GN | 1 |
| Estey, E | 1 |
| Raad, I | 1 |
| Giles, F | 1 |
| Cortes, J | 1 |
| Shen, Y | 1 |
| Kontoyiannis, D | 1 |
| Koller, C | 1 |
| Munsell, M | 1 |
| Beran, M | 1 |
| Kantarjian, H | 2 |
| Masood, A | 1 |
| Sallah, S | 1 |
| Nomura, K | 1 |
| Kawasugi, K | 1 |
| Morimoto, T | 1 |
| Tatetsu, H | 1 |
| Asou, N | 1 |
| Nakamura, M | 1 |
| Hanaoka, N | 1 |
| Matsuno, F | 1 |
| Horikawa, K | 1 |
| Mitsuya, H | 1 |
| Wang, HP | 1 |
| Yen, YF | 1 |
| Chen, WS | 1 |
| Chou, YL | 1 |
| Tsai, CY | 1 |
| Chang, HN | 1 |
| Chou, CT | 1 |
| Nakagawa, Y | 1 |
| Cornely, OA | 1 |
| Winston, DJ | 1 |
| Perfect, J | 1 |
| Ullmann, AJ | 1 |
| Walsh, TJ | 2 |
| Helfgott, D | 1 |
| Holowiecki, J | 1 |
| Stockelberg, D | 1 |
| Goh, YT | 1 |
| Petrini, M | 1 |
| Hardalo, C | 1 |
| Suresh, R | 1 |
| Angulo-Gonzalez, D | 1 |
| Ito, Y | 1 |
| Ohyashiki, K | 1 |
| Yoshida, I | 1 |
| Takeuchi, M | 1 |
| Aoyama, Y | 1 |
| Mugitani, A | 1 |
| Matsuura, Y | 1 |
| Wakita, H | 1 |
| Matsuda, M | 1 |
| Sakamoto, E | 2 |
| Kiguchi, T | 1 |
| Urabe, A | 1 |
| Tamura, K | 1 |
| Kanamaru, A | 1 |
| Masaoka, T | 1 |
| Nakane, T | 1 |
| Yamane, T | 1 |
| Nakamae, H | 1 |
| Ichihara, H | 1 |
| Koh, H | 1 |
| Takeoka, Y | 1 |
| Kanashima, H | 1 |
| Koh, KR | 1 |
| Hino, M | 1 |
| Weiler, S | 1 |
| Bellmann, R | 1 |
| van Nieuwkoop, C | 1 |
| van Dissel, JT | 1 |
| Medlicott, SA | 1 |
| Cox, H | 1 |
| Dupre, M | 1 |
| Lategan, J | 1 |
| Auer, I | 1 |
| Hollaar, G | 1 |
| Debru, E | 1 |
| Conly, J | 1 |
| Katayama, K | 1 |
| Koizumi, S | 1 |
| Yamagami, M | 1 |
| Tamaru, Y | 1 |
| Ichihara, T | 1 |
| Konishi, M | 1 |
| Maekawa, S | 1 |
| Seki, H | 1 |
| Taniguchi, N | 1 |
| Sajben, P | 1 |
| Minárik, T | 1 |
| Tomásik, E | 1 |
| Mardiak, J | 1 |
| Danisovicovà, A | 1 |
| Trupl, T | 1 |
| Krcméry, V | 1 |
| Martino, R | 1 |
| Nomdedéu, J | 1 |
| Altés, A | 1 |
| Sureda, A | 1 |
| Brunet, S | 1 |
| Martínez, C | 1 |
| Domingo-Albós, A | 1 |
| Zweegman, S | 1 |
| Sibinga, L | 1 |
| Huijgens, PC | 1 |
| Epstein, JB | 1 |
| Ransier, A | 1 |
| Lunn, R | 1 |
| Chin, E | 1 |
| Jacobson, JJ | 1 |
| Le, N | 1 |
| Reece, D | 1 |
| Keiser, G | 1 |
| Schmid, M | 1 |
| Ishak, KG | 1 |
| Wirth, W | 1 |
| Vogt, M | 1 |
| Barnes, AJ | 1 |
| Wardley, AM | 1 |
| Oppenheim, BA | 1 |
| Morgenstern, GR | 1 |
| Scarffe, JH | 1 |
| Warnock, DW | 1 |
| Johnson, EM | 1 |
| Nolte, FS | 1 |
| Parkinson, T | 1 |
| Falconer, DJ | 1 |
| Dix, S | 1 |
| Williams, J | 1 |
| Gilmore, C | 1 |
| Geller, R | 1 |
| Myoken, Y | 2 |
| Sugata, T | 2 |
| Kyo, T | 2 |
| Fujihara, M | 2 |
| Mikami, Y | 2 |
| Kumar, RR | 1 |
| Kumar, BR | 1 |
| Shafiulla, M | 1 |
| Lakshmaiah, KC | 1 |
| Sridhar, H | 1 |
| Colović, M | 1 |
| Lazarević, V | 1 |
| Colović, R | 1 |
| Janković, G | 1 |
| Suvajdzić, N | 1 |
| Bogdanović, A | 1 |
| Bila, J | 1 |
| Persson, L | 1 |
| Vikerfors, T | 1 |
| Sjöberg, L | 1 |
| Engervall, P | 1 |
| Tidefelt, U | 1 |
| Smith, KJ | 1 |
| Welsh, M | 1 |
| Skelton, H | 1 |
| Rókusz, L | 1 |
| Liptay, L | 1 |
| Kádár, K | 1 |
| Buchta, V | 1 |
| Zák, P | 1 |
| Kohout, A | 1 |
| Otcenásek, M | 1 |
| Park, YH | 1 |
| Lee, S | 1 |
| Min, CK | 1 |
| Kim, DW | 1 |
| Lee, JW | 2 |
| Shin, WS | 1 |
| Kim, CC | 1 |
| Tanaka, J | 1 |
| Kasai, M | 1 |
| Masauzi, N | 1 |
| Watanabe, M | 1 |
| Matsuura, A | 1 |
| Morii, K | 1 |
| Kiyama, Y | 1 |
| Naohara, T | 1 |
| Higa, T | 1 |
| Hashino, S | 1 |
| Seibel, NL | 1 |
| Amantea, M | 1 |
| Whitcomb, P | 1 |
| Pizzo, PA | 1 |
| Blade, J | 1 |
| Lopez-Guillermo, A | 1 |
| Rozman, C | 1 |
| Grañena, A | 1 |
| Bruguera, M | 1 |
| Bordas, J | 1 |
| Cervantes, F | 1 |
| Carreras, E | 1 |
| Sierra, J | 1 |
| Montserrat, E | 1 |
| Flannery, MT | 1 |
| Simmons, DB | 1 |
| Saba, H | 1 |
| Altus, P | 1 |
| Wallach, PM | 1 |
| Adelman, HM | 1 |
| Anaissie, E | 1 |
| Bodey, GP | 1 |
| David, C | 1 |
| Barnett, K | 1 |
| Bow, E | 1 |
| Defelice, R | 1 |
| Downs, N | 1 |
| File, T | 1 |
| Karam, G | 1 |
| Herbrecht, R | 1 |
| Liu, KL | 1 |
| Koenig, H | 1 |
| Waller, J | 1 |
| Dufour, P | 1 |
| Maloisel, F | 1 |
| Bergerat, JP | 1 |
| Oberling, F | 1 |
| Kidd, D | 1 |
| Ranaghan, EA | 1 |
| Morris, TC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)[NCT01307579] | Phase 3 | 517 participants (Actual) | Interventional | 2011-04-04 | Completed | ||
| A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis[NCT03112031] | Phase 2 | 50 participants (Actual) | Interventional | 2017-10-10 | Completed | ||
| A Phase II Trial to Evaluate the Safety and Tolerability of Nebulised Amphotericin B Lipid Complex (ABELCET®) in the Prophylaxis of Invasive Pulmonary Aspergillosis During Prolonged Neutropenia in Paediatric Patients With Acute Leukaemia[NCT01615809] | Phase 2 | 32 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Randomized Controlled Trial of Posaconazole (SCH 56592) vs. Standard Azole Therapy for the Prevention of Invasive Fungal Infections Among High-Risk Neutropenic Patients[NCT00044486] | Phase 3 | 602 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Revision of Antifungal Strategies Definitions for Invasive Fungal Infections (Proven/Probable/Possible) in Patients With Hematological Malignancies (REDEFI-SEIFEM)[NCT04024995] | 513 participants (Actual) | Observational [Patient Registry] | 2019-09-01 | Completed | |||
| Invasive Fungal Infections in Patients Following Stem Cell Transplant[NCT04619147] | 300 participants (Anticipated) | Observational | 2021-01-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Kaplan Meier method will be used to estimate overall survival. Time to event is from enrollment to date of death (by any cause). Participants are censored at last contact or 2 years anniversary of enrollment into this study, whichever occurred first. (NCT01307579)
Timeframe: Up to 2 years post enrollment
| Intervention | Percentage of participants (Number) |
|---|---|
| Arm I (Caspofungin Acetate) | 68.8 |
| Arm II (Fluconazole) | 70.8 |
The percentage of participants requiring empiric antifungal therapy will be determined based on the presence of prolonged fever and neutropenia during each neutropenia course. (NCT01307579)
Timeframe: Up to 5 months since enrollment
| Intervention | Percentage of participants (Number) |
|---|---|
| Arm I (Caspofungin Acetate) | 71.9 |
| Arm II (Fluconazole) | 69.5 |
Proven or probable invasive aspergillosis (IA) is defined according to the criteria developed by the EORTC/MSG. Kaplan Meier approach will used to estimate the incidence. (NCT01307579)
Timeframe: Up to 5 months since enrollment
| Intervention | Percentage of participants (Number) |
|---|---|
| Arm I (Caspofungin Acetate) | 0.5 |
| Arm II (Fluconazole) | 3.1 |
Proven or probable IFI is defined according to criteria developed by the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG). (NCT01307579)
Timeframe: Up to 5 months since enrollment
| Intervention | Percentage of participants (Number) |
|---|---|
| Arm I (Caspofungin Acetate) | 3.1 |
| Arm II (Fluconazole) | 7.2 |
The incidence of invasive pulmonary aspergillosis during the Abelcet® prophylactic treatment period was assessed by the relation between the number of patients with invasive pulmonary aspergillosis and the number of paediatric patients on prophylaxis with Acute Leukaemia (AL) undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks
| Intervention | participants (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 3 |
Percentage of deaths related to Invasive Pulmonary Aspergillosis during the prophylactic treatment period with Abelcet® in paediatric patients with Acute Leukaemia undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks
| Intervention | percentage of deaths (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 0 |
is assessed by the proportion of patients who discontinue prophylactic treatment with Abelcet® due to an adverse event that is related or not to the study drug or for intolerability to it. The last week of treatment will have a different calendar for each participant, depending on the number of cicles needed by each patient (it has been anticipated up to 5 cicles of 2-6 weeks each). (NCT01615809)
Timeframe: at the Baseline visit (week 1) and during the Last week of treatment, up to 6 weeks
| Intervention | participants (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 0 |
4 reviews available for fluconazole and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis.
Topics: Adult; Antifungal Agents; Aspergillus; Candida; Cost-Benefit Analysis; Female; Fluconazole; Hematopo | 2016 |
Successful intensive chemotherapy followed by autologous hematopoietic cell transplantation in a patient with acute myeloid leukemia and hepatosplenic candidiasis: case report and review of literature.
Topics: Adult; Antifungal Agents; Candida tropicalis; Candidiasis; Caspofungin; Cytarabine; Echinocandins; F | 2009 |
Chronic disseminated candidiasis in patients with acute leukemia: emphasis on diagnostic definition and treatment.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Chronic Disease; Fluconazole; Humans; Leukemia, Myel | 2005 |
Case report. Disseminated infection of Blastoschizomyces capitatus in a patient with acute myelocytic leukaemia.
Topics: Amphotericin B; Antifungal Agents; Fatal Outcome; Fluconazole; Humans; Leukemia, Myeloid, Acute; Mal | 2001 |
11 trials available for fluconazole and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer.
Topics: Antifungal Agents; Caspofungin; Fluconazole; Hematopoietic Stem Cell Transplantation; Humans; Leukem | 2023 |
Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Antifungal Agents; Aspergillosis; Caspofungin; Child; Child, Preschool; Early Ter | 2019 |
Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Area Under Curve; Benzothiazoles; Cytoch | 2019 |
No difference between posaconazole and fluconazole antifungal prophylaxis and mycological diagnostics except costs in patients undergoing AML chemotherapy: a 1-year "real-life" evaluation.
Topics: Adult; Aged; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Laboratory | 2014 |
[Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome].
Topics: Administration, Oral; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protoc | 2010 |
Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Drug Thera | 2003 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Capsules; Female; Fluconazole; Humans; Itraconazole; Jap | 2007 |
Fluconazol plus ofloxacin in prophylaxis of infections in patients with acute leukemia: a comparative study.
Topics: Adult; Bacterial Infections; Drug Costs; Drug Therapy, Combination; Female; Fluconazole; Humans; Inc | 1993 |
Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: a prospective randomized trial.
Topics: Adult; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; Drug Ther | 2002 |
Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy.
Topics: Adult; Aged; Amphotericin B; Candidiasis; Child, Preschool; Chronic Disease; Female; Fluconazole; Hu | 1991 |
57 other studies available for fluconazole and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Topics: Animals; Apoptosis; Candida albicans; Cell Cycle; Cell Line, Tumor; Histone Deacetylase 6; Histone D | 2018 |
Outcomes of pediatric acute myeloid leukemia treatment in Western Kenya.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Doxorubicin; Etoposide; Fluconazo | 2022 |
Catheter-associated blood stream infections due to Candida pararugosa in a patient with acute myeloid leukemia: A case report.
Topics: Adult; Antifungal Agents; Catheter-Related Infections; Catheters; Child, Preschool; Drug Resistance, | 2023 |
Assessing the impact of prophylactic anidulafungin during remission induction of acute myeloid leukemia - A propensity-score matching analysis.
Topics: Adult; Anidulafungin; Antifungal Agents; Fluconazole; Humans; Leukemia, Myeloid, Acute; Propensity S | 2023 |
Prophylaxis Against Invasive Fungal Disease for Neutropenic Children and Young Adults.
Topics: Antifungal Agents; Caspofungin; Child; Fluconazole; Humans; Leukemia, Myeloid, Acute; Mycoses; Young | 2020 |
Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Topics: Administration, Oral; Antineoplastic Agents; Area Under Curve; Computer Simulation; Cytochrome P-450 | 2020 |
Antifungal prophylaxis in newly diagnosed AML patients-Adherence to guidelines and feasibility in a real life setting.
Topics: Adult; Aged; Antifungal Agents; Female; Fluconazole; Galactose; Guideline Adherence; Guidelines as T | 2017 |
Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain.
Topics: Adult; Aged; Antifungal Agents; Cost-Benefit Analysis; Female; Fluconazole; Humans; Invasive Fungal | 2017 |
Disseminated coccidioidomycosis masquerading as recurrent lymphoma.
Topics: Antifungal Agents; Coccidioides; Coccidioidomycosis; Diagnosis, Differential; Female; Fluconazole; G | 2018 |
Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Chemoprevention; Consolidation Chemotherapy; Economics, | 2013 |
Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.
Topics: Aged; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III | 2014 |
Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; C | 2016 |
Management of Invasive Fungal Infections in Pediatric Acute Leukemia and the Appropriate Time for Restarting Chemotherapy.
Topics: Adolescent; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Prescho | 2015 |
Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
Topics: Adult; Antibiotic Prophylaxis; Antifungal Agents; Antineoplastic Agents; Cost Savings; Cost-Benefit | 2015 |
Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.
Topics: Adult; Antifungal Agents; Female; Fluconazole; Humans; Incidence; Induction Chemotherapy; Leukemia, | 2015 |
Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital.
Topics: Antifungal Agents; Cost-Benefit Analysis; Decision Support Techniques; Fluconazole; Hong Kong; Hospi | 2016 |
Acute isolated appendicitis due to Aspergillus carneus in a neutropenic child with acute myeloid leukemia.
Topics: Acute Disease; Acyclovir; Amphotericin B; Antifungal Agents; Appendicitis; Aspergillosis; Aspergillu | 2016 |
Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Topics: Adolescent; Adult; Aged; Allografts; Antifungal Agents; Blood Donors; Female; Fluconazole; Hematopoi | 2016 |
Treatment of aspergillosis.
Topics: Antifungal Agents; Aspergillosis; Fluconazole; Humans; Itraconazole; Leukemia, Myeloid, Acute; Myelo | 2008 |
Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
Topics: Adult; Aged; Antifungal Agents; Costs and Cost Analysis; Female; Fluconazole; Humans; Itraconazole; | 2008 |
Hepatosplenic candidiasis imaged with F-18 FDG PET/CT.
Topics: Antifungal Agents; Candidiasis; Fluconazole; Fluorodeoxyglucose F18; Humans; Leukemia, Myeloid, Acut | 2009 |
Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis.
Topics: Antifungal Agents; Antineoplastic Agents; Canada; Cost Savings; Cost-Benefit Analysis; Decision Supp | 2011 |
Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis.
Topics: Adult; Antifungal Agents; Antimetabolites, Antineoplastic; Cytarabine; Dose-Response Relationship, D | 2010 |
Invasive fungal infections in pediatric patients with hematologic malignancies receiving oral amphotericin B solution and early intravenous administration of fluconazole.
Topics: Administration, Oral; Adolescent; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Aspergil | 2011 |
Candida albicans cervical lymphadenitis in patients who have acute myeloid leukemia.
Topics: Antifungal Agents; Candida albicans; Candidiasis; Fluconazole; Humans; Immunocompromised Host; Leuke | 2011 |
Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antifungal Agents; Female; Fluco | 2012 |
Distinct clinical features of infectious complications in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis in the Nagasaki transplant group.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Bacterial Infections; Cytomegalovirus Infections; Female | 2013 |
Clinical microbiological case: chronic disseminated candidiasis unresponsive to treatment.
Topics: Adult; Amphotericin B; Antifungal Agents; Candida; Candidiasis; Chronic Disease; Fluconazole; Humans | 2002 |
Clinical cases in transplantation.
Topics: Adult; Aged; Amphotericin B; Aspergillus fumigatus; Candida; Candida glabrata; Female; Fluconazole; | 2002 |
Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Cohort Studies; Cost-Benefit Analys | 2006 |
Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Fluconazole; Humans; Leuk | 2006 |
An unusual case of Candida tropicalis and Candida krusei arthritis in a patient with acute myelogenous leukemia before chemotherapy.
Topics: Aged; Antifungal Agents; Arthritis, Infectious; Candida; Candidiasis; Fatal Outcome; Fluconazole; Hu | 2007 |
[Prophylactic administration of fluconazole and itraconazole in febrile neutropenia associated with hematopoietic malignancy].
Topics: Fluconazole; Humans; Itraconazole; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic | 2006 |
[Improved outcome in brain abscess during induction in acute myelocytic leukemia].
Topics: Adult; Antifungal Agents; Brain; Brain Abscess; Drug Administration Schedule; Drug Therapy, Combinat | 2007 |
Posaconazole prophylaxis in hematologic cancer.
Topics: Antifungal Agents; Drug Resistance, Fungal; Fluconazole; Humans; Itraconazole; Leukemia, Myeloid, Ac | 2007 |
Posaconazole prophylaxis in hematologic cancer.
Topics: Antifungal Agents; Fluconazole; Humans; Itraconazole; Leukemia, Myeloid, Acute; Mycoses; Myelodyspla | 2007 |
Systemic illnesses unexpectedly presenting as acute appendicitis: case studies.
Topics: Acute Disease; Adult; Amphotericin B; Antifungal Agents; Appendicitis; Candidiasis; Female; Fluconaz | 2008 |
Successful peritransplant therapy in children with active hepatosplenic candidiasis.
Topics: Amphotericin B; Bone Marrow Transplantation; Candidiasis; Child, Preschool; Female; Fluconazole; Hum | 1994 |
Successful bone marrow transplantation in patients with previous invasive fungal infections: report of four cases.
Topics: Administration, Oral; Adolescent; Adult; Amphotericin B; Aspergillosis; Aspergillus; Bone Marrow Tra | 1994 |
[Hepatosplenic candidiasis in patients treated for hemato-oncological disorders].
Topics: Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Candidiasis; Drug Therapy, Combinati | 1994 |
Prophylaxis of candidiasis in patients with leukemia and bone marrow transplants.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Bone Marrow Transplantation; Candidiasis, Oral; Dental C | 1996 |
[Candidiasis of the liver following successful chemotherapy of acute myeloid leukemia (Fab type 6) and recovery with oral fluconazole therapy].
Topics: Aged; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Candidiasis; Female; Flucon | 1996 |
Fatal Candida tropicalis fungaemia in a leukaemic patient receiving fluconazole prophylaxis.
Topics: Antifungal Agents; Candidiasis; Drug Resistance, Microbial; Fluconazole; Fungemia; Humans; Leukemia, | 1996 |
Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia.
Topics: Adolescent; Adult; Amphotericin B; Animals; Antifungal Agents; Candida albicans; Candidiasis; Drug R | 1997 |
Early surgical management of invasive gingival aspergillosis in a neutropenic patient with leukemia: a case report.
Topics: Adult; Amphotericin B; Antifungal Agents; Aspergillosis; Female; Fluconazole; Flucytosine; Gingival | 1997 |
Fusarium solani infection in a patient with acute myelogenous leukemia--a case report.
Topics: Amphotericin B; Antifungal Agents; Dermatomycoses; Female; Fluconazole; Fusarium; Humans; Leukemia, | 1997 |
Hepatosplenic candidiasis after neutropenic phase of acute leukaemia.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Candidiasi | 1999 |
Increased incidence of bacteraemia due to viridans streptococci in an unselected population of patients with acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Antibiotic Prophylaxis; | 2000 |
Trichophyton rubrum showing deep dermal invasion directly from the epidermis in immunosuppressed patients.
Topics: Adolescent; Adult; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Combi | 2001 |
Successful treatment of chronic disseminated candidiasis with fluconazole and a granulocyte-macrophage colony-stimulating factor combination.
Topics: Adult; Antifungal Agents; Candidiasis; Drug Therapy, Combination; Female; Fluconazole; Granulocyte-M | 2001 |
Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia.
Topics: Administration, Oral; Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis, Oral; Capsules; | 2002 |
Successful second allogeneic bone marrow transplantation in a relapsed acute myeloid leukemia patient with fungal liver abscess.
Topics: Adult; Amphotericin B; Bone Marrow Transplantation; Candidiasis; Drug Therapy, Combination; Female; | 1992 |
Safety and pharmacokinetics of fluconazole in children with neoplastic diseases.
Topics: Child; Drug Administration Schedule; Drug Evaluation; Female; Fluconazole; Humans; Kidney; Leukemia, | 1992 |
Chronic systemic candidiasis in acute leukemia.
Topics: Adolescent; Aged; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Candidiasis; Child | 1992 |
Fluconazole in the treatment of hepatosplenic candidiasis.
Topics: Candidiasis; Fluconazole; Humans; Immunocompromised Host; Leukemia, Myeloid, Acute; Liver Diseases; | 1992 |
[Trichosporon capitatum septicemia in immunosuppressed patients].
Topics: Adult; Female; Fluconazole; Humans; Immune Tolerance; Ketoconazole; Leukemia, Myeloid, Acute; Male; | 1990 |
Hypokalaemia in patients with acute myeloid leukaemia after treatment with fluconazole.
Topics: Administration, Oral; Antifungal Agents; Fluconazole; Humans; Hypokalemia; Leukemia, Myeloid, Acute; | 1989 |